Jefferies Animal Health Summit March 27, 2014

2

Special Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our expectations regarding the approval of products; expectations regarding development programs, trials, studies, approvals and commercialization; the sufficiency of financial resources; expected future cash balance and liquidity; expectations regarding in-license initiatives, collaborations and partnerships; and expectations regarding the Company’s plans and opportunities.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; our lack of commercial sales; our failure to obtain any necessary additional financing; our substantial dependence on the success of certain of our lead product candidates, AT-001, AT-002, AT-003, AT-004, AT-005, AT-006 and AT-007; our inability to identify, license, develop and commercialize additional product candidates; our inability to obtain regulatory approval for our existing or future product candidates; the lack of commercial success of our current or future product candidates; uncertainties regarding the outcomes of studies regarding our products; our inability to realize all of the anticipated benefits of our acquisitions of Vet Therapeutics and Okapi Sciences; effects of competition; our failure to attract and keep senior management and key scientific personnel; our complete reliance on third-party manufacturers and third parties to conduct all our target animal studies and certain other development efforts; our lack of a sales organization; our significant costs of operating as a public company; changes in distribution channels for pet therapeutics; consolidation of our customers; impacts of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; our failure to comply with regulatory requirements; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an “emerging growth company,” as defined in the JOBS Act; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; effects of anti-takeover provisions in our charter documents and under Delaware law; and our intention not to pay dividends. These and other important factors discussed under the caption "Risk Factors" in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 26, 2014, along with our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

Safe Harbor Statement

3

Investment Highlights

Large, growing market

De-risked drug development

Private-pay

Portfolio approach

Scalable and capital-efficient

Pure-play, first mover

4

Source: APPA.

Our Market

Large and growing

– 2014E U.S. pet spend of $59B

Insensitive to recent recessions

68% of U.S. households

– 96M cats

– 83M dogs

Medicalization drives growth

– Historically, limited innovation

– Pet therapeutics underrepresented

U.S. Pet Owners Spend ($Billions)

5

The Evolution of Pet Ownership

“Snoopy Generation” “Brian Generation”

Pets are family whose medical needs merit quality care

6

A Favorable Comparison

Multiple Species Steps Direct to Species

~$1.3B ~$10M

~10 Years ~5 Years

Third Party Payer Private Pay

Steep Generic Decline Slow Generic Decline

Difficult & Indirect Accessible & Direct

Pets Humans

De

velo

pm

en

t C

om

me

rcia

l

7

FDA and USDA Timelines FDA Center for Veterinary Medicine

Proof of Concept

INAD

Chemistry, Mfg. & Controls (CMC)

Safety

Effectiveness

Labeling, FOI Summary, Other

Administrative NADA

Year 5Year 1 Year 2 Year 3 Year 4

USDA - Center for Veterinary Biologics

Proof of Concept

Manufacturing

File for Product License

Preclinical

Field Safety and Efficacy

Conditional Product License*

Extended Field Safety and Efficacy Study

Full Product License* Conditional l i censes granted under specia l ci rcumstances

Year 5Year 1 Year 2 Year 3 Year 4

8

Alignment with the Veterinarian

Annual Exams 17%

Diagnostics 17%

Surgery 17% Non-Invasive

Procedures 9%

Pet Food Sales 4%

Heartworm Product Sales

6%

Flea-Tick Product Sales

6%

Vaccinations 15%

Source: DVM Newsmagazine’s State of the Profession Report 2012.

Innovation is valued and desired

Medicines are high margin to practice

Facing pressure from alternative channels

Other Pharma 9%

Practice Revenue Mix

9

Our Pipeline

Proof of Concept Pilot Pivotal / Commercial

AT-009 Mast Cell – Dog

AT-002 Cat Appetite Stimulant

AT-004 Dog B-Cell Lymphoma

AT-010 Dog Atopic Dermatitis

AT-003 Dog Post-operative Pain

AT-005 Dog T-Cell Lymphoma

AT-011 Dog Canine Parvovirus

AT-003 Cat Post-operative pain

AT-001 Dog Osteoarthritis

AT-012 Cat Feline Calicivirus

AT-007 Cat Feline Immunodeficiency virus

AT-002 Dog Appetite Stimulant

AT-001 Cat Osteoarthritis

AT-008 Dog Lymphoma

AT-006 Cat Feline Herpesvirus

Lymphoma Diagnostic AT-014 Dog

Osteosarcoma

Option 2 Beta

Option 3 Gamma

10

Animal Health Landscape

Total number of NADAs NADAs for dogs / cats Pet therapeutic NCEs*

2011 12 6 2

2012 11 6 0

2013 6 4 2

* NCE defined as new chemical entity not previously approved in humans or animals (excluding parasite drugs).

11

Development News Flow

AT-001 Pivotal study in dogs

AT-002 Pivotal study in dogs

AT-003 PoC in cats and dogs

AT-001 Pilot study in cats

AT-003 U.S. approval

AT-001 U.S. approval

AT-002 U.S. approval

AT-005 Full study in dogs

AT-003 Pivotal study in dogs

AT-009 Pilot study in dogs

AT-012 PoC in cats

AT-011 PoC in dogs

AT-010 Pilot study in dogs

AT-005 Full license AT-005 Conditional license

AT-007 Pivotal study in cats

AT-007 Pilot study in cats

AT-006 Pivotal in cats (EU)

6 Approvals

8 Pivotal Data Sets

10+ Pilot / PoC

AT-008 Pivotal in dogs (EU)

AT-002 Pilot study in cats

AT-009 PoC in dogs

AT-002 Pivotal study in cats

2014 2015 2016

AT-004 Full license

12

Robust Patent Portfolio Small Molecules

Focus on patent-protected innovation

Robust patent portfolio

22 granted & 5 pending US patents licensed

4 Antiviral patents licensed from KU Leuven

– 4 additional patent applications

Foreign counterparts filed in major markets

Human pharmaceutical patents

– Composition of matter

– Manufacturing

– Formulation

– Use

Pursuing additional pet therapeutic patents

Biologics

Speciesization of mAbs

– Counterparts in major markets (expiration 2029)

• Claims directed to heterochimeric mAb

• Covers all VX products

– Dependent claims directed to both CD52 & CD20 mAbs

– Divisional directed to methods of treatment, continuation directed to novel CD20 antigen

mAb Constant Domain Regions

‒ Counterparts in major markets (expiration 2030)

‒ Covers all VX products, including CD52 and CD20 mAbs

mAbs Directed to CD20 (at least 2031)

mAbs Directed to CD52 (at least 2031)

Unpublished applications directed to mAbs against other targets of interest

13

Portfolio Expansion Criteria

Toxicology data are available

Effectiveness data are available

Manufacturing is scaled-up

Key Attributes

Unmet medical need

High incidence or prevalence

Known mechanism of action

Nuance in science

“Early de-risking”

Early De-Risking

Leveraging the investment in human therapeutics Pharmaceuticals Biologics US and EU

14

Why Oncology?

High incidence

Life saving, tangible proposition

Established customer Base

Owners increasingly demand treatment

Existing market of off label human drugs

Area of unmet need

15

Immuno-Oncology

Boosting global immune reaction

Forcing recognition of cancer cells

antigen-specific

Educating the immune system against a specific cancer

antigen-specific

Selective activation of immune cell subset antigen-independent

Non-specific immunotherapy

Therapeutic mAbs

Therapeutic Vaccines

mAbs targeting immunity

checkpoints

1980 1990 2000 2010

IFN or IL-2 in renal cell cancer

or melanoma

Rituxan in follicular lymphoma, Herceptin

in breast cancer

Provenge in prostate cancer

IFN or IL-2 in renal cell cancer

or melanoma

16

Pet Antibodies A proprietary platform

Pet specific antibodies with 85%+ pet sequences

Pet Fc region

Most effective IgG sequence

Straightforward engineering with no shuffling

IP protected

Mouse Pet Specific

Highly specific ‒ Developed against pet targets

Non immunogenic ‒ Compatible with pet immune

system

Highly potent ‒ Engages pet immune system

Cost effective ‒ High yield production

heavy chain

light chain

VH

VL CH1

CH2

CH3

CL

Proprietary Platform Pet Specific Antibodies

17

Oncology Is Target-Rich

Chemotherapy Human Cancer Use Pet Cancer Use

Cyclophosphamide Lymphomas MM, solid tumors

Doxorubicin Lymphomas MM, solid tumors

Vincristine Lymphomas MM, solid tumors

Prednisone Lymphomas MM, solid tumors

L-asparaginase Leukemia, Lymphoma

Carboplatin Solid Tumors

Cis-platinum Sarcoma, Carcinoma, Lymphoma

Mitoxantrone Breast cancer, AML, Lymphomas

Lomustine Brain/CNS, Lymphoma, Mast cell

Methotrexate Lymphomas Osteosarcoma

Antibody Human Cancer Use Pet Cancer Use

Rituxan (CD20) Non-Hodgkin's Lymphoma X

Avastin (VEGF) Solid Tumors X

Erbitux (EGFR) Solid Tumors X

Herceptin (HER2) Breast Cancer X

Campath (CD52) Chronic Lymphocytic Leukemia X

Mylotarg (CD33) Acute Myeloid Leukemia X

Zevalin (CD20) Follicular Lymphoma X

Bexxar (CD20) Non-Hodgkin's Lymphoma X

Vectibix (EGFR) Solid Tumors X

TheraCIM (EGFR) Solid Tumors X

Human Chemo Market

Currently no protein market Immunogenicity Lack of efficacy

Human drugs migrate unchanged into veterinary practice

Human Cancer Antibody Market

18

Canine Lymphoma Ideal for first antibody therapy

A canine-specific antibody therapy could achieve in dogs what Rituxan has done for human lymphoma

Lymphoma is most common blood cancer in dogs

- 6% of total dog cancer

Lymphoma is the most treated cancer

- Chemotherapy is the current “standard of care”

- Approximately 300,000 dogs diagnosed per year (U.S.)

- Treatment cost ranges between $2,500 and $10,000

Clinical manifestations are similar to humans

Lymphocyte targeting has proven efficacious in pets

Hemangiosarcoma

Sarcoma

Lymphoma

Mast Cell

Skin

Bone Other

RITUXAN-LIKE APPROACH FOR DOG LYMPHOMA

Incidence

19

Pet Immunotherapy The Advaxis Platform

Modified live bacteria ‒ Listeria monocytogenes

Genetically modified ‒ Virulence factors deleted

‒ Tumor associated antigen genes added

Multiple constructs available ‒ Targeting human cervical, prostate, breast cancer, melanoma

Manufactured in Europe under GMP

Additional targets under development

Immuno-oncology named Science Magazine 2013 Breakthrough of the Year

20

Pet Immunotherapy

MHC II

MHC I

CD4+ T Cell

CD8+ T Cell

LLO mediated escape

Activated Dendritic Cell

tLLO_ TAA Fusion Protein

21

Osteosarcoma Survival

Survival of Data 4:Survival proportions

0 200 400 600 8000

20

40

60

80

100Legend

Legend

Days

Pe

rce

nt s

urv

iva

l

MST (control) – 239.5 days

MST (vaccinated) – not reached

p=0.032

Survival proportions: Survival of Data 1

Time

Pe

rce

nt

su

rviv

al

0 100 200 300 4000

50

100 Control

Vaccine

Vaccine Control

Repeat IV administration of 1 x 109 CFU of AT-014 is well tolerated in immune competent dogs

Minor side effects at administration (toxicity grade <1)

‒ Mild fever, increased blood pressure, malaise, nausea, and vomiting

No significant side effects

‒ Cardiovascular, Hematopoeitic, Hepatic or Renal systems

Preliminary : AT-014 when used in the adjuvant setting prolongs overall survival in dogs with Her2/neu positive OSA

22

Advaxis Collaboration Next Three Products

3 Products each with:

– Pivotal (USDA or FDA) trial initiation milestones

– US dog approval milestones

– US cat approval milestones

– EU dog approval milestones

– EU cat approval milestones

– Sales milestones per product

Cumulative sales milestones for all 4 products

Tiered royalty per US cumulative net sales for all 4 products

– Mid single digit (maximum 10%)

Split royalty for OUS partnered sales

23

Canine Oncology Leadership Mammary Tumors/

Other Her2/Neu Tumors

Mast Cell Tumors

Osteosarcoma

Undisclosed Tumor Type

Lymphoma B-Cell Lymphoma

T-Cell Lymphoma

Red = Aratana antibody Blue = Advaxis immunotherapy

Incidence

Mast Cell Tumor 13%

Lymphoma 8%

Melanoma 5%

Hemangiosarcoma 5%

Osteosarcoma 5%

Squamous Cell Carcinoma 4%

Fibrosarcoma 4%

Mammary Tumor 2%

Transitional Cell Carcinoma 2%

Thyroid Tumor 1%

Histiocytoma 1%

Undisclosed Tumor Type

Source: Brakke Cancer Report.

24

Top Cancer Treatment States

Board Certified Veterinary Oncologists

25

• Toxicology data are available

• Efficacy data are available

• Manufacturing is scaled-up

Focused In-Licensing Strategy

Key Attributes

• Unmet medical need

• High incidence or prevalence

• Known mechanism of action

• Nuance in science

• “Early de-risking”

Early De-Risking

Leveraging the investment in human therapeutics

26

Why Atopic Dermatitis?

High level of incidence

Opportunity to bring innovative human

science to pets

Existing market focused on treatment

of symptoms

New mechanisms treat the underlying disease rather than

symptoms

Others are building the market

Area of unmet need

27

Atopic Dermatitis Market Size

Source: CL King Zoetis report January 27, 2014.

Significant market opportunity as reflected in recent analyst projections of other development stage products

28

Atopic Dermatitis Canine biology is similar to humans

Angiocentric accumulation of inflammatory cells:

Eosinophils*

Memory T-helper

Mast cells*

IgE+ dendritic

CD52 rich targets

29

Treating the symptoms Antihistamines

30

Treating the Symptoms Apoquel

• Apoquel is a janus kinase inhibitor (oclacitinib) which seems to work via IL-31 induced pruritis

• Costimulation of Th2 cells produced relatively high levels of IL-31

• Apoquel indication: “Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.”

31

Atopic Dermatitis Role of Th2 Cellular Immunity

32

• CRTH2+ Th2 cells preferentially increased in atopic dermatitis

• CRTH2 expressed by 80-90% of allergen-specific Th2 cells

• CRTH2 already validated in asthma, allergic rhinitis and other diseases

Atopic Dermatitis Role of CRTH2 Receptor

33

34

Atopic Dermatitis Asset Screen

3,340 Assets

510 Assets

237 Assets

>10 Assets

Cull Targets: H1, GC receptors, etc.

Cull Route Of Administration: topical, etc.

Other Screens

CD-52 CRTH2

35

Our Financial Profile

Year-end 2013 cash balance $45.7M

Net Loss for the year 2013 was $4.3M – Net Loss $19.7M excluding nonrecurring income tax benefit of $15.4M

Closed Okapi transaction Jan 6, 2014 – Total consideration €33M ($45M)

– Upfront payment of $13.9M

– Okapi promissory note and purchase price consideration of $30M

Closed secondary offering Feb 3, 2014 ‒ Net proceeds of $90.5M

Continue to identify non-dilutive sources of capital ‒ Partnering opportunities globally

‒ Out-licensing of non-core products

‒ Debt instruments

Increased R&D investment

Sufficiently funded through 2015

36

Investment Highlights

Large, growing market

De-risked drug development

Private-pay

Portfolio approach

Scalable and capital-efficient

Pure-play, first mover

37

AT-001 for Osteoarthritis Pain

Medical Need

Established market (U.S. sales $260M, mostly NSAIDs for dogs)

Existing NSAID products have side effects and require monitoring

Safer product for pain and inflammation of osteoarthritis

Our Solution

EP4 receptor antagonist (a novel mechanism)

‒ Potential for significantly improved safety profile vs. Coxibs

Pilot field study completed in 2013

Pivotal field studies to be initiated in 2014, with FDA approval expected in 2016

38

AT-001 Biology

Phospholipids

Arachidonic Acid

Cyclooxygenase (COX)-2

PGE 2(House keeping)

TXA 2 PGI 2

NSAIDs

• GI mucosa

protection

• Platelet

aggregation

• Renal function

regulation

EP2 EP3

Cyclooxygenase (COX)-1

EP1

PGE 2(Inflammatory)

• Pain and Inflammation

EP4 ReceptorOther EP Receptors

COXIBsAT-001 EP4 Receptor

Antagonist

EP4 Receptor • Pain and Inflammation

39

AT-002 for Inappetence

Medical Need

No currently approved product

Effective appetite stimulus to avoid feeding tubes and euthanasia

Seen in aging and chronic conditions

Our Solution

Mimics ghrelin (hunger hormone) to turn on appetite

Statistically significant results on increased appetite and weight gain in dog pilot study

Pivotal field study began in late 2013, with FDA approval expected at the end of 2015 or early 2016

40

AT-002 Biology

Brain

Pituitary gland

Stomach

Intestine

Ghrelin Ghrelin

Increases appetite

Promotes growth hormone secretion

Regulates energy metabolism

Stimulates production of lean body mass

AT-002 Ghrelin Agonist

Growth Hormone (GH)

41

AT-003 for Post-Operative Pain

Medical Need

Pain increasingly recognized and treated

Need for long-acting, non-narcotic post-operative pain relief

Our Solution

Bupivacaine liposome injectable suspension

Pacira launched product for human use in early 2012

Pilot studies began in 2013, with NADA expected in 2016 / early 2017

42

AT-003 Biology

Discrete chambers within a lipid matrix, each filled with bupivacaine liposome

43

Medical Need

Chemo achieves short remissions and has a very high relapse rate

Chemo is harsh on pets and burdensome on owners

Need effective and safe therapy to maintain remission as long as possible

Our Solution

First-in-class product

Effective and safe B-cell depletion

Aid in the treatment of canine B-cell lymphoma

USDA conditional license granted; expect full license in 2015

Market Potential

Approximately 300,000 dogs are diagnosed per year in the U.S.

Canine lymphoma is treated with chemotherapy (like in humans)

Cost to pet owners of lymphoma treatment: ~$5,000

AT-004 Canine-specific antibody for B-cell lymphoma

44

Medical Need

24% of all lymphoma is T cell lymphoma

Our Solution

First-in-class product

Effective and safe T-cell depletion

Aid in the treatment of canine T-cell lymphoma

Submitted for USDA product license; conditional license received in January 2014

AT-005 Canine-specific antibody for T-cell lymphoma

45

Feline Herpes is a common virus in cats

– 97% of cats exposed

– 4% with symptoms in US and EU

– Most prevalent ocular disease

Vaccinations are only option

– Not 100% effective

– Most cats unvaccinated

Similar to humans, virus not cured

AT-006 Feline Herpesvirus

Incidence

Calici

Herpes

FIV

FeLV

FIP

Parvo

46

Treatment of herpetic ocular disease in cats caused by FHV-1 or FVR

Product can be used as a diagnostic as no diagnostic exists

Eyedrops are applied to affected eye

Product is a sterile solution

EMA approval in 2015

Exclusively licensed to Novartis Animal Health globally

AT-006 Feline Herpesvirus

47

FIV is a serious viral disease in cats

– 2.5% incidence in the US

– Incidence is highly variable in Europe ranging from 2.1% to 12.5%

Clinical signs include chronic infections and weight loss, AIDS like symptoms and death

No currently approved antivirals for cats

AT-007 Feline Immunodeficiency Virus

Incidence

Calici

Herpes

FIV

FeLV

FIP

Parvo

48

For the treatment of cats from 6 months of age infected with FIV; same product is active against FeLV (feline leukemia virus)

“Improvement of cat’s well-being and quality of life”

Treatment by injection with a sterile solution over the course of several weeks

Same compound family as Tenofovir, which was developed at KU Leuven

Launch is expected in 2017

AT-007 Feline Immunodeficiency Virus

49

Other Products in Development

Product Species Indication Development Status Expected Next Step

AT-008 Dog Lymphoma Pivotal field effectiveness study

Pivotal field effectiveness in the EU in 2014

AT-009 Dog Mast cell tumor Lead selection Pilot studies

AT-010 Dog Atopic dermatitis Lead selection Pilot studies

AT-011 Dog Parvovirus infections Lead selection Proof of concept study

AT-012 Cat Calicivirus infections Lead selection Proof of concept study

AT-014 Dog Osteosarcoma Pilot studies Pivotal studies